Hot Features
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-con... Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.01 | 0.657894736842 | 1.52 | 1.55 | 1.44 | 48718 | 1.51562608 | CS |
| 4 | -0.06 | -3.77358490566 | 1.59 | 1.59 | 1.43 | 38563 | 1.5008706 | CS |
| 12 | -0.41 | -21.1340206186 | 1.94 | 2.33 | 1.43 | 72286 | 1.84930231 | CS |
| 26 | 0.13 | 9.28571428571 | 1.4 | 2.33 | 1.23 | 95899 | 1.65331375 | CS |
| 52 | -0.54 | -26.0869565217 | 2.07 | 2.33 | 1.23 | 119329 | 1.60795332 | CS |
| 156 | 0.32 | 26.4462809917 | 1.21 | 4.26 | 0.91 | 106941 | 1.98427423 | CS |
| 260 | -1.49 | -49.3377483444 | 3.02 | 6.19 | 0.61 | 134911 | 2.27345479 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.